Aqueduct Neurosciences Inc.:
At LSINW, Aqueduct Neurosciences discussed exciting new technology developments. This year, Aqueduct Neurosciences
presented their new medical device, SED; its purpose is to automatically control pressure and CSF flow in hospitalized
patients with drainage problems. Current devices do not allow the patient to have mobility, which means the patient needs
constant assistance. The new device developed by Aqueduct Neurosciences is a drain device controlled automatically,
allowing the patient to keep his/her mobility and be more autonomous. Consequently, patients will feel better during their
recovery, they will be safer (because the drainage is controlled automatically) and this patient autonomy will improve the
hospital's economics. Aqueduct Neurosciences is looking to partner with someone for the distribution of this SED device.
The technology was developed at the University of Washington, where the licensing is being issued. Their plan is to make
clinical trials post market. Aqueduct Neurosciences is seeking to raise $3 million to be able to afford operation costs
through 2014. Their next step is to test the device for its usefulness in the diagnosis of NPH (Normal Pressure
Hydrocephalus).